Modality
ASO
MOA
Cl18.2
Target
VEGF
Pathway
T-cell
NB
Development Pipeline
Preclinical
~Dec 2011
→ ~Mar 2013
Phase 1
~Jun 2013
→ ~Sep 2014
Phase 2
~Dec 2014
→ ~Mar 2016
Phase 3
~Jun 2016
→ ~Sep 2017
NDA/BLA
~Dec 2017
→ ~Mar 2019
Approved
Jun 2019
→ Dec 2031
ApprovedCurrent
NCT04072634
1,515 pts·NB
2020-03→2031-12·Completed
NCT04663963
2,682 pts·NB
2023-06→2029-02·Completed
NCT06287072
2,226 pts·NB
2024-09→2029-05·Recruiting
+1 more trial
7,807 total pts1 indication
CompletedCurrentUpcoming
Catalysts (4)
2028-09-282.5y awayPh3 Readout· NB
2029-02-032.8y awayPh3 Readout· NB
2029-05-193.1y awayPh3 Readout· NB
2031-12-085.7y awayPh3 Readout· NB
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Active
Approved
Complet…
Approved
Complet…
Approved
Recruit…
Catalysts
Ph3 Readout
2028-09-28 · 2.5y away
NB
Ph3 Readout
2029-02-03 · 2.8y away
NB
Ph3 Readout
2029-05-19 · 3.1y away
NB
Ph3 Readout
2031-12-08 · 5.7y away
NB
RecruitingActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04072634 | Approved | NB | Completed | 1515 | HbA1c |
| NCT04663963 | Approved | NB | Completed | 2682 | SRI-4 |
| NCT06287072 | Approved | NB | Recruiting | 2226 | CR |
| NCT05854304 | Approved | NB | Active | 1384 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |